![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » EU Panel Recommends Roche Hemophilia Drug
EU Panel Recommends Roche Hemophilia Drug
![roche.gif](https://www.fdanews.com/ext/resources/test/Device_Images/roche.gif?t=1600727553&width=430)
January 29, 2018
The EU’s Committee for Medicinal Products for Human recommended Roche’s Hemlibra (emicizumab) for the treatment of hemophilia in certain patients.
The CHMP expressed a positive opinion for use in the routine treatment of bleeding in hemophilia A patients with factor VIII inhibitors who have built up a resistance to standard treatments.
The approval was based on two clinical studies with statistically significant reductions in treated bleeds compared to previous treatments with a bypassing agent.
Upcoming Events
-
21Oct